Jul 7, 2026 04:30PM
Jul 1, 2026 07:00AM
Jul 1, 2026 07:00AM
Jun 1, 2026 04:30PM
May 27, 2026 07:00AM
May 6, 2026 07:15AM
Apr 29, 2026 07:01AM X4 Pharmaceuticals receives EU approval for WHIM syndrome treatment
Apr 29, 2026 07:00AM
Apr 1, 2026 04:30PM
Mar 17, 2026 07:15AM
Mar 9, 2026 06:40AM
Mar 4, 2026 07:00AM
Mar 2, 2026 04:30PM
Feb 27, 2026 07:03AM X4 Pharmaceuticals receives EU committee recommendation for WHIM drug
Feb 27, 2026 07:00AM
Sep 29, 2025 07:30AM
Sep 29, 2025 07:30AM
Sep 8, 2025 07:00AM
Sep 8, 2025 07:00AM
Jun 10, 2025 08:02AM
Jun 10, 2025 08:00AM X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA
Mar 25, 2025 06:01AM
Feb 19, 2025 07:35AM
Feb 19, 2025 07:35AM
Jan 29, 2025 02:48PM
Jan 24, 2025 07:38AM
Jan 24, 2025 07:36AM
Jan 13, 2025 07:35AM X4 Pharmaceuticals (XFOR) and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
Jan 13, 2025 07:35AM
Aug 8, 2024 06:01AM
May 9, 2024 06:30AM
May 9, 2024 06:30AM
May 7, 2024 06:01AM
Apr 29, 2024 06:30AM
Apr 29, 2024 06:30AM X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
Mar 21, 2024 06:01AM
Dec 12, 2023 06:54AM
Nov 9, 2023 06:01AM
Oct 31, 2023 08:02AM
Oct 31, 2023 08:00AM
Oct 18, 2023 08:02AM
Oct 18, 2023 08:00AM X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors
Sep 5, 2023 08:01AM
Sep 5, 2023 08:00AM
Aug 10, 2023 06:05AM
Aug 8, 2023 04:07PM
Aug 8, 2023 04:05PM
May 16, 2023 04:01PM
May 16, 2023 04:01PM X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome
May 15, 2023 09:10AM

326,536 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All